Cheng Dong
Pennsylvania State University, USA

Cheng Dong received his Ph.D. in 1988 from Columbia University. Following two years of postdoctoral studies at the University of California San Diego and additional two years of research training at the National Institutes of Health, he joined the faculty at the Pennsylvania State University in 1992. Dr, Dong is now a Distinguished Professor of Biomedical Engineering and Head of the Penn State Department of Biomedical Engineering.

Dr. Dong is a Member of the United States National Committee on Biomechanics; a Fellow of the Biomedical Engineering Society (BMES); a Fellow of the American Institute of Medical and Biological Engineering (AIMBE); a Council Member of the International Society of Biorheology; a past Chair of the BMES Cellular & Molecular Bioengineering Special Interest Group; and a past Secretary of the national Biomedical Engineering Council of Chairs. He is also a Managing Editor for Frontiers in Bioscience; an Associate Editor for BMES Cellular and Molecular Bioengineering; and an Associate Editor for Molecular and Cellular Biomechanics; as well as an Editorial Member of Medicine in Novel Technology and Devices, and the Chinese Journal of Medical Biomechanics. Dr. Dong was a recipient of the National Science Foundation’s Faculty Career Award; American Cancer Society Faculty Research Award; American Society of Mechanical Engineers (ASME) Y.C. Fung Young Investigator Award; ASME Melville Medal; ASME Best Journal Paper Award; and BMES Harold Lamport Young Investigator Award.

A major focus of Dr. Dong’s research is on micro-hemodynamics, intercellular and intracellular signaling, biomechanics in oncology, cancer immunology and metastases. In particular, he investigates how tumor microenvironment change leukocyte and/or endothelial immune functions which subsequently affect tumor cell extravasation and subsequent metastasis. In most recent years, Dr. Dong collaborates with material scientists and neural science biologists on development of immune cell-mediated nanoparticle and drug delivery across the blood-brain barrier targeting brain tumors.